We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Based on the results of a phase 2 trial, UK-based Synairgen said Monday that its antiviral SNG001 reduced the risk of severe disease in hospitalized COVID-19 patients. Read More
Preliminary data from a German phase 1/2 trial showed that Pfizer’s and BioNTech’s mRNA-based coronavirus vaccine candidate is safe and generated immune responses in participants, the companies announced Monday. Read More
In a first glimpse at the efficacy of a COVID-19 vaccine from AstraZeneca and the University of Oxford, highly anticipated clinical data found that it produces strong immune response. Read More
Once hailed by President Trump and others as a possible treatment for COVID-19, the antimalarial drug hydroxychloroquine continues to a thumbs down in a number of human studies, most recently for treatment of patients with mild infections and for hospitalized patients. Read More
Johnson & Johnson has announced that it will begin evaluating its experimental COVID-19 vaccine in its first clinical trial next week, beginning in Belgium on July 22 and the U.S. the following week. Read More